

FORM PTO-1390
(REV 12-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

NEX88/PCT-US

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10/030725

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

INTERNATIONAL APPLICATION NO.
PCT/US00/20478

INTERNATIONAL FILING DATE
26 JULY 2000

PRIORITY DATE CLAIMED
29 JULY 1999

TITLE OF INVENTION HIGH AFFINITY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR
NUCLEIC ACID LIGANDS AND INHIBITORS

APPLICANT(S) FOR DO/EO/US JANJIC, Nebojsa; GOLD, Larry

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:


1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ has been communicated by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:
Abstract; Application Data Sheet; Postcard Receipt; Statement Under 37 C.F.R. §1.821

20478-013102

2015-01-11 10:52:00

<div style="display: flex; justify-content: space-between;"> U.S. APPLICATION NO. (if known, see 37 CFR 1.51) 107/030725 INTERNATIONAL APPLICATION NO. PCT/US00/20478 </div>		<div style="display: flex; justify-content: space-between;"> 1072 Rec'd PCT/PTO 11 JAN 2002 </div>	
ATTORNEY'S DOCKET NUMBER NEX88/PCT-US			
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =		CALCULATIONS PTO USE ONLY	
		\$ 710.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	14 - 20 =		x \$18.00
Independent claims	3 - 3 =		x \$84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00
TOTAL OF ABOVE CALCULATIONS =		\$ 710.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		+	
SUBTOTAL =		\$ 710.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$	
TOTAL NATIONAL FEE =		\$	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +		\$	
TOTAL FEES ENCLOSED =		\$ 710.00	
		Amount to be refunded:	\$
		charged:	\$
a. <input type="checkbox"/> A check in the amount of \$ _____ to cover the above fees is enclosed. b. <input checked="" type="checkbox"/> Please charge my Deposit Account No. <u>22-0277</u> in the amount of \$ <u>710.00</u> to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>22-0277</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: <div style="display: flex; justify-content: space-between;"> <div> ROSEMARY KELLOGG Customer No. 25,871 SWANSON & BRATSCHUN, L.L.C. 1745 Shea Center Drive, Suite 330 Highlands Ranch, Colorado 80129 UNITED STATES OF AMERICA </div> <div style="text-align: right;"> January 11, 2002  SIGNATURE ROSEMARY KELLOGG NAME 39,726 REGISTRATION NUMBER </div> </div>			

10/030725

**HIGH AFFINITY VASCULAR ENDOTHELIAL GROWTH FACTOR
(VEGF) RECEPTOR NUCLEIC ACID LIGANDS AND INHIBITORS**

5 **FIELD OF THE INVENTION**

Described herein are methods for identifying and preparing high affinity nucleic acid ligands that bind to a VEGF receptor. The method utilized herein for identifying such nucleic acid ligands is called SELEX, an acronym for Systematic Evolution of Ligands by EXponential Enrichment. This invention includes high affinity nucleic acids to a VEGF
10 receptor. Further disclosed are RNA ligands to a VEGF receptor. Also included are oligonucleotides containing nucleotide derivatives modified at the 2' position of the pyrimidines. Additionally disclosed are ligands to a VEGF receptor containing 2'-F modifications of the pyrimidines. This invention also includes high affinity nucleic acid inhibitors of VEGF signaling. The oligonucleotide ligands of the present invention are
15 useful in any process in which binding of VEGF to a VEGF receptor is required. This includes, but is not limited to, their use as pharmaceuticals, diagnostics, imaging agents, and immunohistochemical reagents.

BACKGROUND OF THE INVENTION

20 **Angiogenesis in disease**

The growth of new blood vessels from existing endothelium (angiogenesis) is tightly controlled in healthy adults by opposing effects of positive and negative regulators. Under certain pathological conditions, including proliferative retinopathies, rheumatoid arthritis, psoriasis and cancer, positive regulators prevail and angiogenesis contributes to disease
25 progression (reviewed in Folkman (1995) *Nature Med.* 1:27-31). In cancer, the notion that angiogenesis represents the rate limiting step of tumor growth and metastasis (Folkman (1971) *New Engl. J. Med.* 285:1182-1186) is now supported by considerable experimental evidence (reviewed in Aznavoorian *et al.* (1993) *Cancer* 71:1368-1383; Fidler and Ellis (1994) *Cell* 79:185-188; Folkman (1990) *J. Natl. Cancer Inst.* 82:4-6). The quantity of blood
30 vessels in tumor tissue is a strong negative prognostic indicator in breast cancer (Weidner *et al.* (1992) *J. Natl. Cancer Inst.* 84:1875-1887), prostate cancer (Weidner *et al.* (1993) *Am. J. Pathol.* 143:401-409), brain tumors (Li *et al.* (1994) *Lancet* 344:82-86), and melanoma (Foss *et al.* (1996) *Cancer Res.* 56:2900-2903).

VEGF signaling in angiogenesis

- A number of angiogenic growth factors have been described to date among which vascular endothelial growth factor (VEGF) appears to play a key role as a positive regulator of physiological and pathological angiogenesis (reviewed in Brown *et al.* (1997) in Control of Angiogenesis (Goldberg and Rosen, eds.), Birkhauser, Basel, 233-269; Thomas (1996) J. Biol. Chem. 271:603-606; Neufeld *et al.* (1999) FASEB J. 13:9-22). VEGF is a secreted disulfide-linked homodimer that selectively stimulates endothelial cells to proliferate, migrate, and produce matrix-degrading enzymes (Conn *et al.* (1990) Proc. Natl. Acad. Sci. U.S.A. 87:1323-1327; Ferrara and Henzel (1989) Biochem. Biophys. Res. Commun. 161:851-858; Gospodarowicz *et al.* (1989) Proc. Natl. Acad. Sci. U.S.A. 86:7311-7315; Pepper *et al.* (1991) Biochem. Biophys. Res. Commun. 181:902-906; Unemori *et al.* (1992) J. Cell. Physiol. 153:557-562), all of which are processes required for the formation of new vessels. In addition to being the only known endothelial cell specific mitogen, VEGF is unique among angiogenic growth factors in its ability to induce a transient increase in blood vessel permeability to macromolecules (hence its original and alternative name, vascular permeability factor) (Dvorak *et al.* (1979) J. Immunol. 122:166-174; Senger *et al.* (1983) Science 219:983-985; Senger *et al.* (1986) Cancer Res. 46:5629-5632). Increased vascular permeability and the resulting deposition of plasma proteins in the extravascular space assists the new vessel formation by providing a provisional matrix for the migration of endothelial cells (Dvorak *et al.* (1995) Am. J. Pathol. 146:1029-1039). Hyperpermeability is indeed a characteristic feature of new vessels, including those associated with tumors (Dvorak *et al.* (1995) Am. J. Pathol. 146:1029-1039). Furthermore, compensatory angiogenesis induced by tissue hypoxia is now known to be mediated by VEGF (Levy *et al.* (1996) J. Biol. Chem. 271:2746-2753); Shweiki *et al.* (1992) Nature 359:843-845).
- VEGF is produced and secreted in varying amounts by virtually all tumor cells (Brown *et al.* (1997) in Control of Angiogenesis (Goldberg and Rosen, eds.), Birkhauser, Basel:233-269). Direct evidence that VEGF and its receptors contribute to tumor growth was recently obtained by a demonstration that the growth of human tumor xenografts in nude mice could be inhibited by neutralizing antibodies to VEGF (Kim *et al.* (1993) Nature 362:841-844), by the expression of dominant-negative VEGFR2 (Millauer *et al.* (1996) Cancer Res. 56:1615-1620; Millauer *et al.* (1994) Nature 367:576-579), by low molecular weight inhibitors of VEGF receptor inhibitors (Strawn *et al.* (1966) Cancer Res. 56:3540-3545), or by the expression of antisense sequence to VEGF mRNA (Saleh *et al.* (1996)

10030725-0134172

Cancer Res. 56:393-401). Importantly, the incidence of tumor metastases was also found to be dramatically reduced by VEGF antagonists (Asano *et al.* (1995) Cancer Res. 55:5296-5301; Warren *et al.* (1995) J. Clin. Invest. 95:1789-1797; Claffey *et al.* (1996) Cancer Res. 56:172-181; Melnyk *et al.* (1996) Cancer Res. 56:921-924). Inhibitors of VEGF signaling may thus have broad clinical utility as anticancer agents. In addition to cancer, as noted above, other proliferative diseases characterized by excessive neovascularization such as psoriasis, age-related macular degeneration, diabetic retinopathy and rheumatoid arthritis could be treated with antagonists of VEGF signaling.

VEGF occurs in several forms (VEGF-121, VEGF-145, VEGF-165, VEGF-189, VEGF-206) as a result of alternative splicing of the VEGF gene that consists of eight exons (Houck *et al.* (1991) Mol. Endocrin. 5:1806-1814; Tischer *et al.* (1991) J. Biol. Chem. 266:11947-11954; Poltorak *et al.* (1997) J. Biol. Chem. 272:7151-7158). The three smaller forms are diffusable, while the larger two forms remain predominantly localized to the cell membrane as a consequence of their high affinity for heparin. VEGF-165 and VEGF-145 also bind to heparin (as a consequence of containing basic exon 7- and exon 6-encoded domains, respectively), albeit with somewhat lower affinity compared with VEGF-189 (that contains both exons 6 and 7). VEGF-165 appears to be the most abundant form in most tissues (Houck *et al.* (1991) Mol. Endocrinol. 5:1806-1814; Carmeliet *et al.* (1999) Nature Med. 5:495-502). VEGF-121, the only alternatively spliced form that does not bind to heparin, appears to have a somewhat lower affinity for the receptors (Gitay-Goren *et al.* (1996) J. Biol. Chem. 271:5519-5523) as well as lower mitogenic potency (Keyt *et al.* (1996) J. Biol. Chem. 271:7788-7795).

VEGF receptors

Biological effects of VEGF are mediated by two homologous tyrosine kinase receptors, Flt-1 (VEGFR1) and Flk-1/KDR (VEGFR2) whose expression is highly restricted to cells of endothelial origin (de Vries *et al.* (1992) Science 255:989-991; Millauer *et al.* (1993) Cell 72:835-846; Terman *et al.* (1991) Oncogene 6:519-524). Both receptors have an extracellular domain consisting of seven IgG-like domains, a transmembrane domain and an intracellular tyrosine kinase domain. The affinity of VEGFR1 for VEGF ($K_d = 1-20$ pM) is higher compared to that of VEGFR2 ($K_d = 50-770$ pM) (Brown *et al.* (1997) in Regulation of Angiogenesis, *supra*; de Vries *et al.* (1992) Science 255:989-991; Terman *et al.* (1992) Biochem. Biophys. Res. Commun. 187:1579-1586). In human umbilical cord endothelial cells (HUVECs) in 2-dimensional culture, VEGFR2 is by far the more abundant receptor

(Brown *et al.* (1997) in Regulation of Angiogenesis, *supra*). *In vivo*, however, in quiescent endothelial cells, both receptors are expressed at low levels (Kremer *et al.* (1997) *Cancer Res.* 57:3852-3859; Barleon *et al.* (1997) *Cancer Res.* 57:5421-5425).

Both receptors are substantially upregulated when endothelial cells are activated by a variety of stimuli. Hypoxia, for example, induces an increase in expression of both VEGFR1 and VEGFR2 in endothelial cells (Tuder *et al.* (1995) *J. Clin. Invest.* 95:1798-1807; Gerber *et al.* (1997) *J. Biol. Chem.* 272:23659-23667; Brogi *et al.* (1996) *J. Clin. Invest.* 97:469-476; Kremer *et al.* (1997) *Cancer Res.* 57:3852-3859). For VEGFR1, hypoxia leads to both direct activation via the *flt-1* promoter that contains the hypoxia-inducible-factor-1 (HIF-1) consensus binding site (Gerber *et al.* (1997) *J. Biol. Chem.*, *supra*) and indirect activation via hypoxia-induced VEGF (Barleon *et al.* (1997) *Cancer Res.*, *supra*). VEGF-induced upregulation of VEGFR1 is mediated by both VEGFR1 and VEGFR2 (Barleon *et al.* (1997) *Cancer Res.*, *supra*). VEGFR2 is upregulated by VEGF (through VEGFR2, but not VEGFR1) (Kremer *et al.* (1997) *Cancer Res.*, *supra*; Wilting *et al.* (1996) *Dev. Biol.* 176:76-85) and possibly by a yet unidentified factor in hypoxia-conditioned media from myoblasts (Brogi *et al.* (1996) *J. Clin. Invest.*, *supra*). The expression of VEGFR2 in endothelial cells is also upregulated by bFGF and this accounts in part for the synergistic activation of endothelial cells by VEGF and bFGF (Pepper *et al.* (1998) *Exp. Cell Res.* 241:414-425). In addition, since both *kdr* and *flt-1* promoters contain a cis-acting fluid shear-stress-responsive element, VEGFR1 and VEGFR2 expression may be sensitive to variations in blood flow (Tuder *et al.* (1995) *J. Clin. Invest.*, *supra*).

Experiments using porcine aortic endothelial (PAE) cells transfected with the *flt-1* or *kdr* receptor genes have suggested that VEGFR2 is the primary transducer in endothelial cells of VEGF-mediated signals related to changes in cell morphology and mitogenicity (Waltenberger *et al.* (1994) *J. Biol. Chem.* 269:26988-26995). In the same study, stimulation of *flt-1*-transfected PAE cells with VEGF did not appear to produce detectable changes. More recently, however, it was demonstrated that VEGF signaling through VEGFR1 induces migration of monocytes and upregulation of tissue factor expression in both endothelial cells and monocytes (Clauss *et al.* (1996) *J. Biol. Chem.* 271:17629-17634; Barleon *et al.* (1996) *Blood* 87:3336-3343). Based on the observation that the extracellular domain of VEGFR2 is retained on a cation exchange resin only in the presence of VEGFR1 and that the VEGFR2 retention is enhanced when both VEGFR1 and VEGF were present, Kendall *et al.* have concluded that the two receptors have some affinity for one another and that this interaction

is stabilized by VEGF (Kendall *et al.* (1996) *Biochem Biophys. Res. Commun.* 226:324-328). When both receptors are expressed on cell surface, it appears likely that the VEGFR1/R2 heterodimer constitutes at least a fraction of the binding-competent VEGF receptor.

5 Gene deletion studies of VEGF and VEGF receptors

The functions of VEGFR1 and VEGFR2 have further been elucidated by targeted gene deletion studies. While deletion of either VEGFR1 or VEGFR2 results in embryonic lethality as a result of vascular abnormalities, there are important differences in the two phenotypes.

10 In mice deficient in VEGFR1, endothelial cells are formed but organize into distended and dilated vessels (Fong *et al.* (1995) *Nature* 376:66-70). Interestingly, mice that only lack the tyrosine Chinese domain of VEGFR1 (and thus display the receptor on cell surfaces that is incapable of signaling) are viable, with the only detectable abnormality being the strongly suppressed macrophage migration in response to VEGF (Hiratsuka *et al.* (1998) Proc. Natl. Acad. Sci. 95:9349-9354). Since vascular abnormalities of VEGFR1 knockout mice are similar to those observed in transgenic mice that overexpress VEGF during development, it has been suggested that VEGFR1 is primarily a negative regulator of VEGF signaling, and that partial inhibition of VEGF signaling is essential for proper vessel development (Hiratsuka *et al.* (1998) *Proc. Natl. Acad. Sci.*, *supra*). It is relevant to note in this context that VEGFR1 also exists as an alternatively spliced secreted extracellular domain that acts as a potent inhibitor of VEGF (Kendall *et al.* (1993) *Proc. Natl. Acad. Sci., U.S.A.* 90:10705-10709). The importance of tightly controlled VEGF signaling during development is further evidenced by the lethal phenotype of mice that lack only one allele of the VEGF gene (Carmeliet *et al.* (1996) *Nature* 380:435-439; Ferrara *et al.* (1996) *Nature* 380:439-442) and also of mice that only express the smallest isoform of VEGF (VEGF-120) (Carmeliet *et al.* (1999) *Nature Med.* 5:495-502). Thus, deviations on either side from a precisely determined level of VEGF signaling results in embryonic lethality.

Mice deficient in VEGFR2 lack both endothelial cells and hematopoietic cells, a more severe phenotype compared to that of VEGFR1 knockout, that results in embryonic lethality at day 8 (Shalaby *et al.* (1995) *Nature* 376:62-66). This is presumably a consequence of the fact that these two cell types arise from a common, VEGFR2-expressing precursor, the hemangioblast (Eichmann *et al.* (1997) *Proc. Natl. Acad. Sci.* 94:5141-5146).

Structural requirements for binding

Crystal structure of the receptor-binding domain of VEGF (residues 8-109) has recently been reported (Muller *et al.* (1997) Proc. Natl. Acad. Sci., U.S.A. 94:7192-7197; Muller *et al.* (1997) Structure 5:1325-1338). In the VEGF homodimer, the monomers are oriented in an antiparallel manner with two intersubunit disulfide bonds being formed between Cys51 from one subunit and Cys60 from the other. The three intrasubunit disulfide bonds are clustered in a characteristic cysteine knot motif (Sun *et al.* (1995) Annu. Rev. Biophys. Biomol. Struct. 24:269-291) also observed in PDGF and TGF β 2. Despite low sequence homology (about 20%), PDGF and VEGF have very similar structures. Both proteins have an elongated shape in which each of the subunits consist primarily of four antiparallel β strands connected with three solvent accessible loops. In the homodimer, loops I and III from one subunit are adjacent to loop II from the other subunit. Alanine-scanning mutagenesis studies of VEGF have identified discrete regions that are important for high affinity binding to VEGFR1 and VEGFR2 (Keyt *et al.* (1996) J. Biol. Chem. 271:5638-5646; Muller *et al.* (1997) Proc. Natl. Acad. Sci., U.S.A. 94:7192-7197). Amino acid residues most critical for binding of VEGF to VEGFR1 are D63 and E64 in loop II. Residues most critical for binding of VEGF to VEGFR2 are R82-H86 encompassing loop III, I46 in loop I and E64 in loop II. Knowledge of the importance of these regions for receptor binding has been utilized to generate VEGF mutants in which only one side of the VEGF homodimer was rendered defective for receptor binding (Siemeister *et al.* (1998) Proc. Natl. Acad. Sci., U.S.A. 95:4625-4629; Fuh *et al.* (1998) J. Biol. Chem. 273:11197-11204). As expected, such monovalent VEGF mutants are inhibitors of VEGF-induced signaling since they are deficient in their ability to dimerize the receptors. Interestingly, avidity effects play a greater role in the binding of VEGF to VEGFR2 than to VEGFR1. The affinity of monomeric VEGFR1 for wild-type VEGF dimer is reduced only about 2-fold compared to that of dimeric VEGFR1 (IgG fusion construct) (Weismann *et al.* (1997) Cell 91:695-704). In contrast, the affinity of monomeric VEGFR2 for VEGF is reduced 100-fold compared to the dimeric VEGFR2 (Fuh *et al.* (1998) J. Biol. Chem., *supra*). Comparing only the monomeric forms, VEGFR1 binds to VEGF with about 100-fold higher affinity compared to VEGFR2.

Domain deletion studies of the extracellular region of the VEGF receptors have shown that out of seven IgG-like domains, domains 2 and 3 of VEGFR1 (Davis-Smyth *et al.* (1996) EMBO J. 15:4919-4927; Barleon *et al.* (1997) J. Biol. Chem. 272:10382-10388) and VEGFR2 (Fuh *et al.* (1998) J. Biol. Chem. 273:11197-11204; Shinkai *et al.* (1998) J. Biol.

Chem. 273:31283-31288) are essential for VEGF binding. The crystal structure of the complex between VEGF₈₋₁₀₉ with IgG domain 2 of VEGFR1 (that bind to VEGF with only 60-fold reduced affinity compared to the entire extracellular domain of the receptor) shows the receptor to be in contact with both subunits of VEGF₈₋₁₀₉ in an interaction dominated by hydrophobic contacts (Weismann *et al.* (1997) *Cell, supra*).

VEGF-165 receptors

In addition to VEGFR1 and VEGFR2, receptors that only bind VEGF-165 and not VEGF-121 have been identified on endothelial cells and some tumor cells (Soker *et al.* (1996) *J. Biol. Chem.* 271:5761-5767; Soker *et al.* (1997) *J. Biol. Chem.* 272:31582-31588; Omura *et al.* (1997) *J. Biol. Chem.* 272:23317-23322). One such receptor unrelated in sequence to the tyrosine kinase receptors and with a short cytoplasmic domain, neuropilin-1, is also a receptor for semaphorins which play a role in neuronal chemorepulsion during development (Soker *et al.* (1998) *Cell* 92:735-745). Since the binding of VEGF-165 to neuropilin-1 involves the exon 7-encoded domain that is not required for the binding to VEGFR1 and VEGFR2, it has been suggested that neuropilin-1 serves as a co-receptor for VEGF-165. The presence of such receptors on endothelial cells may in part account for the enhanced mitogenic activity of VEGF-165 compared to VEGF-121. Consistent with this notion is the observation that cardiovascular system of neuropilin-1 knockout mice does not develop normally leading to embryonic lethality (Kitsukawa *et al.* (1997) *Neuron* 19:995-1005). The questions of what role VEGF may play in neuronal development and conversely, whether semaphorins have a role in vascular development and function, remain to be answered.

Receptor binding specificity of various forms of VEGF and other proteins in the VEGF family

In addition to the alternatively spliced forms of VEGF, additional species can be generated by proteolytic processing. Plasmin cleaves VEGF-165 and VEGF-189 between residues Arg-110 and Ala-111 to generate VEGF-110 as the amino terminus fragment (Keyt *et al.* (1996) *J. Biol. Chem., supra*; Plouët *et al.* (1997) *J. Biol. Chem.* 272:13390-13396). Since it contains the receptor binding domain (*supra*), VEGF-110 bind to both VEGFR1 and VEGFR2. Like VEGF-121, VEGF-110 does not bind to heparin and its potency is lower compared to that of VEGF-165 (Keyt *et al.* (1996) *J. Biol. Chem., supra*). Interestingly, VEGF-189 can bind to VEGFR1, but not VEGFR2 and this renders it inactive as an endothelial cell mitogen (Houck *et al.* (1991) *Mol. Endocrinol., supra*; Plouët *et al.* (1997) *J.*

Biol. Chem. 272, *supra*). VEGF-189 thus requires proteolytic processing either by plasmin or by urokinase-type plasminogen activator (that cleaves VEGF-189 in the exon 6-encoded domain to generate a 40 kDa fragment) to gain ability to bind to VEGFR2 (Plouët *et al.* (1997) J. Biol. Chem., *supra*).

5 Proteins with sequence homology to VEGF (also referred to as VEGF-A) have recently been described including placenta growth factor (PlGF: Park *et al.* (1994) J. Biol. Chem. 269:25646-25654), VEGF-B (Olofsson *et al.* (1996) Proc. Natl. Acad. Sci., U.S.A. 93:2576-2581), VEGF-C (Lee *et al.* (1996) Proc. Natl. Acad. Sci., U.S.A. 93:1988-1992; Joukov *et al.* (1996) EMBO J. 15:290-298), VEGF-D (Achen *et al.* (1998) Proc. Natl. Acad. Sci., U.S.A. 95:548-553) and VEGF-E (Ogawa *et al.* (1998) J. Biol. Chem. 273:31273-31282). In terms of receptor binding specificity, PlGF and VEGF-B can bind only to VEGFR1 with high affinity. VEGF-C and VEGF-D bind to VEGFR2 and another related tyrosine kinase, Flt-4 or VEGFR3. The expression of VEGFR3 appears to be confined to lymphatic endothelial cells. VEGF-E, a protein encoded in the genome of the Orf virus,
10 binds only to VEGFR2 (Ogawa *et al.* (1998) J. Biol. Chem. 273:31273-31282). Some of these proteins including PlGF and VEGF-B can form heterodimers with VEGF (Cao *et al.* (1996) J. Biol. Chem. 271:3154-3162; DiSalvo *et al.* (1996) J. Biol. Chem. 270:7717-7723). The function of these VEGF-related molecules in physiological and pathological conditions remains to be precisely defined, however, it is clear that some redundancy of signaling
15 mediated by VEGF receptors exists (Nicosia (1998) Am. J. Pathol. 153:11-16).

VEGF receptors on non-endothelial cells

Although VEGFR1 and VEGFR2 are expressed predominantly on endothelial cells, they have also been detected on some non-endothelial cells. VEGFR1 is expressed on trophoblasts (Charnockjones *et al.* (1994) Biol. Reprod. 51:524-530), monocytes (Barleon *et al.* (1996) Blood, *supra*), hematopoietic stem cells and megakaryocytes/platelets (Katoh *et al.* (1996) Cancer Res. 55:5687-5692), renal mesangial cells (Takahashi *et al.* (1995) Biochem. Biophys. Res. Commun. 209:218-226) and pericytes (Yamagishi *et al.* (1999) Lab. Invest. 79:501-509). In monocytes, VEGFR1 is responsible for the VEGF-mediated induction of migration and tissue factor expression (Clauss *et al.* (1996) J. Biol. Chem., *supra*; Barleon *et al.* (1996) Blood, *supra*; Hiratsuka *et al.* (1998) Proc. Natl. Acad. Sci., *supra*). In pericytes,
25 VEGFR1 may mediate the recently described ability of VEGF to act as a mitogen and chemotactic factor (Yamagishi *et al.* (1999) Lab. Invest., *supra*). The role of VEGFR1 in trophoblasts and mesangial cells remains to be elucidated. The expression of VEGFR2 has
30

been detected on hematopoietic stem cells, megakaryocytes/platelets and retinal progenitor cells (Katoh *et al.* (1995) Cancer Res. 55:5687-5692; Yang *et al.* (1996) J. Neurosci. 16:6089-6099). VEGFR1 and VEGFR2 expression has also been reported on malignant cells including leukemia cells (Katoh *et al.* (1995) Cancer Res., *supra*) and melanoma cells (Gitay-Goren *et al.* (1993) Biochem. Biophys. Res. Commun. 190:702-709).

SELEX

A method for the *in vitro* evolution of nucleic acid molecules with high affinity binding to target molecules has been developed. This method, Systematic Evolution of Ligands by EXponential enrichment, termed SELEX, is described in U.S. Patent Application Serial No. 07/536,428, filed June 11, 1990, entitled "Systematic Evolution of Ligands by Exponential Enrichment," now abandoned, U.S. Patent No. 5,475,096, "Nucleic Acid Ligands," and U.S. Patent No. 5,270,163, entitled "Methods for Identifying Nucleic Acid Ligands," (see also WO91/19813), each of which is herein specifically incorporated by reference. Each of these applications, collectively referred to herein as the SELEX Patent Applications, describe a fundamentally novel method for making a nucleic acid ligand to any desired target molecule.

The SELEX method involves selection from a mixture of candidate oligonucleotides and step-wise iterations of binding, partitioning and amplification, using the same general selection theme, to achieve virtually any desired criterion of binding affinity and selectivity. Starting from a mixture of nucleic acids, preferably comprising a segment of randomized sequence, the SELEX method includes steps of contacting the mixture with the target under conditions favorable for binding, partitioning unbound nucleic acids from those nucleic acids which have bound to target molecules, dissociating the nucleic acid-target complexes, amplifying the nucleic acids dissociated from the nucleic acid-target complexes to yield a ligand-enriched mixture of nucleic acids, then reiterating the steps of binding, partitioning, dissociating and amplifying through as many cycles as desired to yield high affinity nucleic acid ligands to the target molecule.

The basic SELEX method may be modified to achieve specific objectives. For example, U.S. Patent Application Serial No. 07/960,093, filed October 14, 1992, entitled "Method for Selecting Nucleic Acids on the Basis of Structure," now abandoned, describes the use of SELEX in conjunction with gel electrophoresis to select nucleic acid molecules with specific structural characteristics, such as bent DNA (see U.S. Patent No. 5,707,796). U.S. Patent Application Serial No. 08/123,935, filed September 17, 1993, entitled

"Photoselection of Nucleic Acid Ligands," now abandoned, describes a SELEX based method for selecting nucleic acid ligands containing photoreactive groups capable of binding and/or photocrosslinking to and/or photoinactivating a target molecule. U.S. Patent Application Serial No. 08/134,028, filed October 7, 1993, entitled "High-Affinity Nucleic Acid Ligands That Discriminate Between Theophylline and Caffeine", now abandoned, describes a method for identifying highly specific nucleic acid ligands able to discriminate between closely related molecules, termed "Counter-SELEX" (see U.S. Patent No. 5,580,737). U.S. Patent Application Serial No. 08/143,564, filed October 25, 1993, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Solution SELEX", now abandoned, (see also U.S. Patent No. 5,567,588) and U.S. Patent No. 5,861,254, entitled "Flow Cell SELEX", describe SELEX-based methods which achieve highly efficient partitioning between oligonucleotides having high and low affinity for a Target molecule. U.S. Patent No. 5,496,938, entitled "Nucleic Acid Ligands to HIV-RT and HIV-1 Rev," describes methods for obtaining improved nucleic acid ligands after the SELEX process has been performed. U.S. Patent No. 5,705,337, entitled "Systematic Evolution of Ligands by EXponential Enrichment: Chemi-SELEX", describes methods for covalently linking a ligand to its target.

The SELEX method encompasses the identification of high-affinity nucleic acid ligands containing modified nucleotides conferring improved characteristics on the ligand, such as improved *in vivo* stability or delivery. Examples of such modifications include chemical substitutions at the ribose and/or phosphate and/or base positions. Specific SELEX-identified nucleic acid ligands containing modified nucleotides are described in U.S. Patent Application Serial No. 08/117,991, filed September 8, 1993, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," now abandoned, that describes oligonucleotides containing nucleotide derivatives chemically modified at the 5- and 2'-positions of pyrimidines, as well as specific RNA ligands to thrombin containing 2'-amino modifications (see U.S. Patent No. 5,660,985). U.S. Patent Application Serial No. 08/134,028, *supra*, describes highly specific nucleic acid ligands containing one or more nucleotides modified with 2'-amino (2'-NH₂), 2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe). U.S. Patent Application Serial No. 08/264,029, filed June 22, 1994, entitled "Novel Method of Preparation of Known and Novel 2' Modified Nucleosides by Intramolecular Nucleophilic Displacement," describes oligonucleotides containing various 2'-modified pyrimidines. PCT/US98/00589 (WO 98/130720), filed January 7, 1998,

entitled "Bioconjugation of Oligonucleotides" describes a method for identifying bioconjugates to a target comprising nucleic acid ligands derivatized with a molecular entity exclusively at the 5'-position of the nucleic acid ligands.

The SELEX method encompasses combining selected oligonucleotides with other selected oligonucleotides and non-oligonucleotide functional units as described in U.S. Patent No. 5,637,459, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Chimeric SELEX," and U.S. Patent No. 5,683,867, entitled "Systematic Evolution of Ligands by Exponential Enrichment: Blended SELEX," respectively. These applications allow the combination of the broad array of shapes and other properties, and the efficient amplification and replication properties, of oligonucleotides with the desirable properties of other molecules. The full text of the above described patent applications, including but not limited to, all definitions and descriptions of the SELEX process, are specifically incorporated herein by reference in their entirety.

BRIEF SUMMARY OF THE INVENTION

The present invention includes methods of identifying and producing nucleic acid ligands to a VEGF receptor and the nucleic acid ligands so identified and produced. A VEGF receptor is any receptor which VEGF binds, including, but not limited to, VEGFR1, VEGFR2, VEGFR3 and neuropilin-1. In particular, RNA sequences are provided that are capable of binding specifically to a VEGF receptor. Also included are oligonucleotides containing nucleotide derivatives modified at the 2' position of the pyrimidines. Specifically included in the invention are the RNA ligand sequences shown in **Tables 2 and 3** and **Figure 1** (SEQ ID NOS:2-36). Also included in this invention are RNA ligands of a VEGF receptor that inhibit the function of VEGF signaling.

Further included in this invention is a method of identifying nucleic acid ligands and nucleic acid ligand sequences to a VEGF receptor, comprising the steps of (a) preparing a candidate mixture of nucleic acids; (b) contacting the candidate mixture of nucleic acids with a VEGF receptor; (c) partitioning between members of said candidate mixture on the basis of affinity to a VEGF receptor; and (d) amplifying the selected molecules to yield a mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity for binding to a VEGF receptor.

More specifically, the present invention includes the RNA ligands to a VEGF receptor, identified according to the above-described method, including those ligands

shown in **Tables 2** and **3** and **Figure 1** (SEQ ID NOS:2-36). Also included are nucleic acid ligands to a VEGF receptor that are substantially homologous to any of the given ligands and that have substantially the same ability to bind a VEGF receptor and inhibit VEGF signaling. Further included in this invention are nucleic acid ligands to a VEGF receptor that have substantially the same structural form as the ligands presented herein and that have substantially the same ability to bind a VEGF receptor and inhibit VEGF signaling.

The present invention also includes other modified nucleotide sequences based on the nucleic acid ligands identified herein and mixtures of the same.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 shows the predicted secondary structures for representative nucleic acid ligands from Table 2.

Figure 2 depicts the results of the Flk-1 SELEX experiment described in Example 4.

DETAILED DESCRIPTION OF THE INVENTION

The central method utilized herein for identifying nucleic acid ligands to a VEGF receptor is called the SELEX process, an acronym for Systematic Evolution of Ligands by EXponential enrichment and involves (a) contacting the candidate mixture of nucleic acids with a VEGF receptor; (b) partitioning between members of said candidate mixture on the basis of affinity to a VEGF receptor; and, (c) amplifying the selected molecules to yield a mixture of nucleic acids enriched for nucleic acid sequences with a relatively higher affinity for binding to a VEGF receptor.

The invention also includes RNA ligands to a VEGF receptor. This invention further includes the specific RNA ligands to a VEGF receptor shown in **Tables 2** and **3** and **Figure 1**.

SELEX is described in U.S. Patent Application Serial No. 07/536,428, entitled "Systematic Evolution of Ligands by EXponential Enrichment," now abandoned, U.S. Patent No. 5,475,096, entitled "Nucleic Acid Ligands," and U.S. Patent No. 5,270,163, entitled "Methods for Identifying Nucleic Acid Ligands," (see also WO91/19813). These applications, each specifically incorporated herein by reference, are collectively called the SELEX Patent Applications. VEGF nucleic acid ligands have been described in U.S.

Patent Application Serial No. 09/156,824, filed September 18, 1998, U.S. Patent No. 5,849,479 and U.S. Patent No. 5,811,533, each entitled "High Affinity Oligonucleotide Ligands to Vascular Endothelial Growth Factor (VEGF)," U.S. Patent Application Serial No. 08/870,930, filed June 6, 1997, U.S. Patent Application Serial No. 09/254,968, filed March 16, 1999, and U.S. Patent No. 6,051,698, each entitled "Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes." These applications are each specifically incorporated herein by reference.

Certain terms used to described the invention herein are defined as follows:

"**Nucleic acid ligand**" as used herein is a non-naturally occurring nucleic acid having a desirable action on a target. A nucleic acid ligand is also referred to herein as an "aptamer." A desirable action includes, but is not limited to, binding of the target, catalytically changing the target, reacting with the target in a way which modifies/alters the target or the functional activity of the target, covalently attaching to the target as in a suicide inhibitor, and facilitating the reaction between the target and another molecule. In the preferred embodiment, the desirable action is specific binding to a target molecule, such target molecule being a three dimensional chemical structure other than a polynucleotide that binds to the nucleic acid ligand through a mechanism which predominantly depends on Watson/Crick base pairing or triple helix binding, wherein the nucleic acid ligand is not a nucleic acid having the known physiological function of being bound by the target molecule. Nucleic acid ligands include nucleic acids that are identified from a candidate mixture of nucleic acids, said nucleic acid ligand being a ligand of a given target by the method comprising: a) contacting the candidate mixture with the target, wherein nucleic acids having an increased affinity to the target relative to the candidate mixture may be partitioned from the remainder of the candidate mixture; b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids.

"**Candidate mixture**" is a mixture of nucleic acids of differing sequence from which to select a desired ligand. The source of a candidate mixture can be from naturally-occurring nucleic acids or fragments thereof, chemically synthesized nucleic acids, enzymatically synthesized nucleic acids or nucleic acids made by a combination of the foregoing techniques. In a preferred embodiment, each nucleic acid has fixed sequences surrounding a randomized region to facilitate the amplification process.

"Nucleic acid" means either DNA, RNA, single-stranded or double-stranded and any chemical modifications thereof. Modifications include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil, backbone modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping.

"SELEX" methodology involves the combination of selection of nucleic acid ligands that interact with a target in a desirable manner, for example binding to a protein, with amplification of those selected nucleic acids. Iterative cycling of the selection/amplification steps allows selection of one or a small number of nucleic acids that interact most strongly with the target from a pool which contains a very large number of nucleic acids. Cycling of the selection/amplification procedure is continued until a selected goal is achieved. In the present invention, the SELEX methodology is employed to obtain nucleic acid ligands to a VEGF receptor. The SELEX methodology is described in the SELEX Patent Applications.

"Target" means any compound or molecule of interest for which a ligand is desired. A target can be a protein, peptide, carbohydrate, polysaccharide, glycoprotein, hormone, receptor, antigen, antibody, virus, substrate, metabolite, transition state analog, cofactor, inhibitor, drug, dye, nutrient, growth factor, etc. without limitation. In this application, the target is a VEGF receptor.

In its most basic form, the SELEX process may be defined by the following series of steps:

- 1) A candidate mixture of nucleic acids of differing sequence is prepared. The candidate mixture generally includes regions of fixed sequences (i.e., each of the members of the candidate mixture contains the same sequences in the same location) and regions of randomized sequences. The fixed sequence regions are selected either: (a) to assist in the amplification steps described below; (b) to mimic a sequence known to bind to the target; or (c) to enhance the concentration of a given structural arrangement of the nucleic acids in the candidate mixture. The randomized sequences can be totally randomized (i.e., the

probability of finding a base at any position being one in four) or only partially randomized (e.g., the probability of finding a base at any location can be selected at any level between 0 and 100 percent).

2) The candidate mixture is contacted with the selected target under conditions favorable for binding between the target and members of the candidate mixture. Under these circumstances, the interaction between the target and the nucleic acids of the candidate mixture can be considered as forming nucleic acid-target pairs between the target and those nucleic acids having the strongest affinity for the target.

3) The nucleic acids with the highest affinity for the target are partitioned from those nucleic acids with lesser affinity to the target. Because only an extremely small number of sequences (and possibly only one molecule of nucleic acid) corresponding to the highest affinity nucleic acids exist in the candidate mixture, it is generally desirable to set the partitioning criteria so that a significant amount of the nucleic acids in the candidate mixture (approximately 5-50%) are retained during partitioning.

4) Those nucleic acids selected during partitioning as having the relatively higher affinity to the target are then amplified to create a new candidate mixture that is enriched in nucleic acids having a relatively higher affinity for the target.

5) By repeating the partitioning and amplifying steps above, the newly formed candidate mixture contains fewer and fewer weakly binding sequences, and the average degree of affinity of the nucleic acids to the target will generally increase. Taken to its extreme, the SELEX process will yield a candidate mixture containing one or a small number of unique nucleic acids representing those nucleic acids from the original candidate mixture having the highest affinity to the target molecule.

The SELEX Patent Applications describe and elaborate on this process in great detail. Included are targets that can be used in the process; methods for partitioning nucleic acids within a candidate mixture; and methods for amplifying partitioned nucleic acids to generate enriched candidate mixture. The SELEX Patent Applications also describe ligands obtained to a number of target species, including both protein targets where the protein is and is not a nucleic acid binding protein.

The SELEX method further encompasses combining selected nucleic acid ligands with lipophilic or non-immunogenic, high molecular weight compounds in a diagnostic or therapeutic complex as described in U.S. Patent No. 6,011,020, entitled "Nucleic Acid Ligand Complexes." VEGF nucleic acid ligands that are associated with a lipophilic

compound, such as diacyl glycerol or dialkyl glycerol, in a diagnostic or therapeutic complex are described in U.S. Patent No. 5,859,228, entitled "Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes". VEGF nucleic acid ligands that are associated with a Lipophilic Compound, such as a glycerol lipid, or a non-immunogenic, high molecular weight Compound, such as polyalkylene glycol, are further described in U.S. Patent Application Serial No. 08/897,351, filed July 21, 1997, entitled "Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes". VEGF nucleic acid ligands that are associated with a non-immunogenic, high molecular weight compound or lipophilic compound are also further described in PCT/US 97/18944, filed October 17, 1997, entitled "Vascular Endothelial Growth Factor (VEGF) Nucleic Acid Ligand Complexes" (WO 98/18480)". Each of the above described patent applications which describe modifications of the basic SELEX procedure are specifically incorporated by reference herein in their entirety.

In certain embodiments of the present invention it is desirable to provide a complex comprising one or more nucleic acid ligands to a VEGF receptor covalently linked with a non-immunogenic, high molecular weight compound or lipophilic compound. A "complex" used herein describes the molecular entity formed by the covalent linking of the nucleic acid ligand of a VEGF receptor to a non-immunogenic, high molecular weight compound. A non-immunogenic, high molecular weight compound is a compound between approximately 100 Da to 1,000,000 Da, more preferably approximately 1000 Da to 500,000 Da, and most preferably approximately 1000 Da to 200,000 Da, that typically does not generate an immunogenic response. For the purposes of this invention, an immunogenic response is one that causes the organism to make antibody proteins. In one preferred embodiment of the invention, the non-immunogenic, high molecular weight compound is a polyalkylene glycol. In the most preferred embodiment, the polyalkylene glycol is polyethylene glycol (PEG). More preferably, the PEG has a molecular weight of about 10-80K. Most preferably, the PEG has a molecular weight of about 20-45K. In certain embodiments of the invention, the non-immunogenic, high molecular weight compound can also be a nucleic acid ligand.

In another embodiment of the invention it is desirable to have a complex comprised of a nucleic acid ligand to a VEGF receptor and a lipophilic compound. Lipophilic compounds are compounds that have the propensity to associate with or partition into lipid and/or other materials or phases with low dielectric constants, including structures that are comprised substantially of lipophilic components. Lipophilic compounds include lipids as well as non-lipid containing compounds that have the propensity to associate with lipid

(and/or other materials or phases with low dielectric constants). Cholesterol, phospholipid, and glycerol lipids, such as dialkylglycerol, diacylglycerol, and glycerol amide lipids are further examples of lipophilic compounds. In a preferred embodiment, the lipophilic compound is a glycerol lipid.

5 The non-immunogenic, high molecular weight compound or lipophilic compound may be covalently bound to a variety of positions on the nucleic acid ligand to a VEGF receptor, such as to an exocyclic amino group on the base, the 5-position of a pyrimidine nucleotide, the 8-position of a purine nucleotide, the hydroxyl group of the phosphate, or a hydroxyl group or other group at the 5' or 3' terminus of the nucleic acid ligand to VEGF
10 receptor. In embodiments where the lipophilic compound is a glycerol lipid, or the non-immunogenic, high molecular weight compound is polyalkylene glycol or polyethylene glycol, preferably the non-immunogenic, high molecular weight compound is bonded to the 5' or 3' hydroxyl of the phosphate group thereof. In the most preferred embodiment, the lipophilic compound or non-immunogenic, high molecular weight compound is bonded to
15 the 5' hydroxyl of the phosphate group of the nucleic acid ligand. Attachment of the non-immunogenic, high molecular weight compound or lipophilic compound to the nucleic acid ligand of VEGF receptor can be done directly or with the utilization of linkers or spacers.

20 A "**linker**" is a molecular entity that connects two or more molecular entities through covalent bonds or non-covalent interactions, and can allow spatial separation of the molecular entities in a manner that preserves the functional properties of one or more of the molecular entities. A linker can also be known as a spacer.

 The complex comprising a nucleic acid ligand to VEGF receptor and a non-immunogenic, high molecular weight compound or lipophilic compound can be further associated with a lipid construct. Lipid constructs are structures containing lipids,
25 phospholipids, or derivatives thereof comprising a variety of different structural arrangements which lipids are known to adopt in aqueous suspension. These structures include, but are not limited to, lipid bilayer vesicles, micelles, liposomes, emulsions, lipid ribbons or sheets, and may be complexed with a variety of drugs and components which are known to be pharmaceutically acceptable. In the preferred embodiment, the lipid construct is a liposome.
30 The preferred liposome is unilamellar and has a relative size less than 200 nm. Common additional components in lipid constructs include cholesterol and alpha-tocopherol, among others. The lipid constructs may be used alone or in any combination which one skilled in the art would appreciate to provide the characteristics desired for a particular application. In

addition, the technical aspects of lipid constructs and liposome formation are well known in the art and any of the methods commonly practiced in the field may be used for the present invention.

The SELEX method further comprises identifying bioconjugates to a target.

- 5 Copending PCT Patent Application No. US98/00589, filed January 7, 1998, entitled "Bioconjugation of Oligonucleotides," (WO 98/30720), describes a method for enzymatically synthesizing bioconjugates comprising RNA derivatized exclusively at the 5'-position with a molecular entity, and a method for identifying bioconjugates to a target comprising nucleic acid ligands derivatized with a molecular entity exclusively at the 5'-
- 10 position of the nucleic acid ligands. A bioconjugate as used herein refers to any oligonucleotide that has been derivatized with another molecular entity. In a preferred embodiment, the molecular entity is a macromolecule. As used herein, a "macromolecule" refers to a large organic molecule. Examples of macromolecules include, but are not limited to nucleic acids, oligonucleotides, proteins, peptides,
- 15 carbohydrates, polysaccharides, glycoproteins, lipophilic compounds, such as cholesterol, phospholipids, diacyl glycerols and dialkyl glycerols, hormones, drugs, non-immunogenic high molecular weight compounds, fluorescent, chemiluminescent and bioluminescent marker compounds, antibodies and biotin, etc. without limitation. In certain embodiments, the molecular entity may provide certain desirable characteristics to the nucleic acid
- 20 ligand, such as increasing RNA hydrophobicity and enhancing binding, membrane partitioning and/or permeability. Additionally, reporter molecules, such as biotin, fluorescein or peptidyl metal chelates for incorporation of diagnostic radionuclides may be added, thus providing a bioconjugate which may be used as a diagnostic agent.

- 25 Certain VEGF receptors (e.g., VEGFR1 and VEGFR2) are strongly upregulated in activated endothelial cells compared to quiescent cells. Activated endothelial cells would be found at areas of inflammation, ischemia reperfusion injury or angiogenesis. Thus, in certain embodiments of the present invention, it is contemplated that VEGF receptor nucleic acid ligands may be used to deliver various chemotherapeutic, radiotherapeutic or imaging entities to such sites.

- 30 Thus, the methods described herein and the nucleic acid ligands identified by such methods are useful for both therapeutic and diagnostic purposes. Therapeutic uses include the treatment or prevention of diseases or medical conditions in human patients. Therapeutic uses may also include veterinary applications. The VEGF receptor nucleic

acid ligands described herein can be used to treat, inhibit, prevent or diagnose any disease state that involves inappropriate VEGF production, particularly angiogenesis.

Angiogenesis rarely occurs in healthy adults, except during the menstrual cycle and wound healing. Angiogenesis is a central feature, however, of various disease states, including,

5 but not limited to cancer, diabetic retinopathy, macular degeneration, psoriasis and rheumatoid arthritis. The present invention, thus, also includes, but is not limited to, methods of treating, inhibiting, preventing or diagnosing diabetic retinopathy, macular degeneration, psoriasis and rheumatoid arthritis. Additionally, VEGF is produced and secreted in varying amounts by virtually all tumor cells. Thus, the present invention,
10 includes methods of treating, inhibiting, preventing, or diagnosing cancer.

Diagnostic utilization may include both *in vivo*, *ex vivo* or *in vitro* diagnostic applications. The SELEX method generally, and the specific adaptations of the SELEX method taught and claimed herein specifically, are particularly suited for diagnostic applications. SELEX identifies nucleic acid ligands that are able to bind targets with high
15 affinity and with surprising specificity. These characteristics are, of course, the desired properties one skilled in the art would seek in a diagnostic ligand.

The nucleic acid ligands of the present invention may be routinely adapted for diagnostic purposes according to any number of techniques employed by those skilled in the art or by the methods described in PCT/US98/00589 (WO 98/30720). Diagnostic
20 agents need only be able to allow the user to identify the presence of a given target at a particular locale or concentration. Simply the ability to form binding pairs with the target may be sufficient to trigger a positive signal for diagnostic purposes. Those skilled in the art would also be able to adapt any nucleic acid ligand by procedures known in the art to incorporate a labeling tag in order to track the presence of such ligand. Such a tag could
25 be used in a number of diagnostic procedures. The nucleic acid ligands to a VEGF receptor described herein may specifically be used for identification of a VEGF receptor protein.

Labeling markers, such as radionuclides, magnetic compounds, and the like can be conjugated to the VEGF receptor nucleic acid ligand for imaging in an *in vivo* or *ex vivo*
30 setting disease conditions in which VEGF receptor is expressed. The marker may be covalently bound to a variety of positions on the VEGF receptor nucleic acid ligand, such as to an exocyclic amino group on the base, the 5-position of a pyrimidine nucleotide, the 8-position of a purine nucleotide, the hydroxyl group of the phosphate, or a hydroxyl

group or other group at the 5' or 3' terminus of the VEGF receptor nucleic acid ligand. In one embodiment, the marker is bonded to the 5' or 3' hydroxyl of the phosphate group thereof. Attachment of the marker can be done directly or with the utilization of a linker.

As discussed above, in other embodiments, the VEGF receptor nucleic acid ligands are useful for the delivery of therapeutic compounds (including, but not limited to, cytotoxic compounds and immune enhancing substances) to tissues or organs expressing VEGF receptor. Conditions in which VEGF receptor may be expressed include, but are not limited to, inflammation, ischemia reperfusion injury and angiogenesis. Those skilled in the art would be able to adapt any VEGF receptor nucleic acid ligand by procedures known in the art to incorporate a therapeutic compound in a complex. The therapeutic compound may be covalently bound to a variety of positions on the VEGF receptor nucleic acid ligand, such as to an exocyclic amino group on the base, the 5-position of a pyrimidine nucleotide, the 8-position of a purine nucleotide, the hydroxyl group of the phosphate, or a hydroxyl group or other group at the 5' or 3' terminus of the VEGF receptor nucleic acid ligand. In one embodiment, the therapeutic agent can be done directly or with the utilization of a linker.

It is also contemplated that both the marker and therapeutic agent may be associated with the VEGF receptor nucleic acid ligand such that detection of the disease condition and delivery of the therapeutic agent is accomplished together. It is also contemplated that either or both the marker and/or the therapeutic agent may be structure, such as a liposome. As discussed above, methods for conjugating nucleic acid ligands with lipophilic compounds or non-immunogenic compounds in a diagnostic or therapeutic complex are described in U.S. Patent No. 6,011,020, entitled "Nucleic Acid Ligand Complexes," which is incorporated herein in its entirety.

Furthermore, VEGFR1 and VEGFR2, for example, belong to a class of tyrosine kinase receptors in which activating phosphorylation and subsequent signaling is initiated by ligand-induced receptor dimerization (Weiss and Schlessinger (1998) Cell 94:277-280). Thus, in certain circumstances, it would be desirable to enhance or control the VEGF signaling. For example, increasing VEGF production may lead to the growth of new blood vessels around a blood clot in heart disease. Surgery may be avoided by having a biochemical alternative. See, for example, Van Velle *et al.* (1998) Circulation 97:381-90. Thus, the VEGF receptor aptamer can be used as a VEGF substitute. Therefore, it is contemplated that nucleic acid ligands in dimeric or multimeric formulations may

reasonably be expected to serve as a receptor agonist, provided that, as would be known to one of skill in the art, the linkage between the aptamers is appropriate to induce productive receptor dimerization.

SELEX provides high affinity ligands of a target molecule. This represents a singular achievement that is unprecedented in the field of nucleic acids research. The present invention applies the SELEX procedure to the specific target of a VEGF receptor. In the Example section below, the experimental parameters used to isolate and identify the nucleic acid ligands to VEGF receptor are described.

In order to produce nucleic acids desirable for use as a pharmaceutical, it is preferred that the nucleic acid ligand (1) binds to the target in a manner capable of achieving the desired effect on the target; (2) be as small as possible to obtain the desired effect; (3) be as stable as possible; and (4) be a specific ligand to the chosen target. In most situations, it is preferred that the nucleic acid ligand have the highest possible affinity to the target.

In co-pending and commonly assigned U.S. Patent No. 5,496,938, methods are described for obtaining improved nucleic acid ligands after SELEX has been performed. This patent, entitled "Nucleic Acid Ligands to HIV-RT and HIV-1 Rev," is specifically incorporated herein by reference.

In the present invention, SELEX experiments were performed in order to identify RNA ligands with specific high affinity for a VEGF receptor. This invention includes the specific RNA ligands to a VEGF receptor shown in **Tables 2** and **3** and **Figure 1** (SEQ ID NOS:2-36), identified by the methods described in Example 1. This invention further includes RNA ligands to a VEGF receptor which inhibit VEGF receptor function, presumably by inhibiting binding of VEGF to its receptor or interfering with productive receptor dimerization that is essential for receptor phosphorylation and subsequent signal transduction. The scope of the ligands covered by this invention extends to all nucleic acid ligands of a VEGF receptor, modified and unmodified, identified according to the SELEX procedure. More specifically, this invention includes nucleic acid sequences that are substantially homologous to the ligands shown in **Tables 2** and **3** and **Figure 1** (SEQ ID NOS:2-36). By substantially homologous it is meant a degree of primary sequence homology in excess of 70%, most preferably in excess of 80%, and even more preferably in excess of 90%, 95% or 99%. The percentage of homology as described herein is calculated as the percentage of nucleotides found in the smaller of the two sequences

which align with identical nucleotide residues in the sequence being compared when 1 gap in a length of 10 nucleotides may be introduced to assist in that alignment. A review of the sequence homologies of the ligands of a VEGF receptor, shown in **Tables 2 and 3** and **Figure 1** (SEQ ID NOS:2-36) shows that some sequences with little or no primary
5 homology may have substantially the same ability to bind a VEGF receptor. For these reasons, this invention also includes nucleic acid ligands that have substantially the same structure and ability to bind a VEGF receptor as the nucleic acid ligands shown in **Tables 2 and 3** and **Figure 1** (SEQ ID NOS:2-36). Substantially the same ability to bind VEGF receptor means that the affinity is within one or two orders of magnitude of the affinity of
10 the ligands described herein. It is well within the skill of those of ordinary skill in the art to determine whether a given sequence -- substantially homologous to those specifically described herein -- has substantially the same ability to bind a VEGF receptor.

This invention also includes nucleic acid ligands that have substantially the same postulated structure or structural motifs. Substantially the same structure or structural
15 motifs can be postulated by sequence alignment using the Zukerfold program (see Zuker (1989) *Science* 244:48-52). As would be known in the art, other computer programs can be used for predicting secondary structure and structural motifs. Substantially the same structure or structural motif of nucleic acid ligands in solution or as a bound structure can also be postulated using NMR or other techniques as would be known in the art.

20 One potential problem encountered in the therapeutic, prophylactic, and *in vivo* diagnostic use of nucleic acids is that oligonucleotides in their phosphodiester form may be quickly degraded in body fluids by intracellular and extracellular enzymes such as endonucleases and exonucleases before the desired effect is manifest. Certain chemical modifications of the nucleic acid ligand can be made to increase the *in vivo* stability of the
25 nucleic acid ligand or to enhance or to mediate the delivery of the nucleic acid ligand. See, e.g., U.S. Patent Application Serial No. 08/117,991, filed September 8, 1993, entitled "High Affinity Nucleic Acid Ligands Containing Modified Nucleotides," now abandoned and U.S. Patent No. 6,011,020, entitled "Nucleic Acid Ligand Complexes," which are specifically incorporated herein by reference. Modifications of the nucleic acid ligands
30 contemplated in this invention include, but are not limited to, those which provide other chemical groups that incorporate additional charge, polarizability, hydrophobicity, hydrogen bonding, electrostatic interaction, and fluxionality to the nucleic acid ligand bases or to the nucleic acid ligand as a whole. Such modifications include, but are not

limited to, 2'-position sugar modifications, 5-position pyrimidine modifications, 8-position purine modifications, modifications at exocyclic amines, substitution of 4-thiouridine, substitution of 5-bromo or 5-iodo-uracil, backbone modifications, phosphorothioate or alkyl phosphate modifications, methylations, unusual base-pairing combinations such as the isobases isocytidine and isoguanidine and the like. Modifications can also include 3' and 5' modifications such as capping.

Where the nucleic acid ligands are derived by the SELEX method, the modifications can be pre- or post- SELEX modifications. Pre-SELEX modifications yield nucleic acid ligands with both specificity for their SELEX target and improved *in vivo* stability. Post-SELEX modifications made to 2'-OH nucleic acid ligands can result in improved *in vivo* stability without adversely affecting the binding capacity of the nucleic acid ligand. The preferred modifications of the nucleic acid ligands of the subject invention are 5' and 3' phosphorothioate capping and/or 3'-3' inverted phosphodiester linkage at the 3' end. In one preferred embodiment, the preferred modification of the nucleic acid ligand is a 3'-3' inverted phosphodiester linkage at the 3' end. Additional 2'-fluoro (2'-F) and/or 2'-amino (2'-NH₂) and/or 2'-O methyl (2'-OMe) and/or 2'-OCH₃ modification of some or all of the nucleotides is preferred. Described herein are nucleic acid ligands that were 2'-F modified and incorporated into the SELEX process. Also described herein are nucleic acid ligands that were 2'-OCH₃ modified after the SELEX process was performed.

Other modifications are known to one of ordinary skill in the art. Such modifications may be made post-SELEX (modification of previously identified unmodified ligands) or by incorporation into the SELEX process.

As described above, because of their ability to selectively bind a VEGF receptor, the nucleic acid ligands to a VEGF receptor described herein are useful as pharmaceuticals. This invention, therefore, also includes a method for treating a VEGF receptor-mediated pathological condition by administration of a nucleic acid ligand capable of binding to a VEGF receptor.

Therapeutic compositions of the nucleic acid ligands may be administered parenterally by injection, although other effective administration forms, such as intraarticular injection, inhalant mists, orally active formulations, transdermal iontophoresis or suppositories, are also envisioned. One preferred carrier is physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers may also be used. In one preferred embodiment, it is envisioned that the carrier and the ligand

constitute a physiologically-compatible, slow release formulation. The primary solvent in such a carrier may be either aqueous or non-aqueous in nature. In addition, the carrier may contain other pharmacologically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation. Similarly, the carrier may contain still other pharmacologically-acceptable excipients for modifying or maintaining the stability, rate of dissolution, release, or absorption of the ligand. Such excipients are those substances usually and customarily employed to formulate dosages for parental administration in either unit dose or multi-dose form.

Once the therapeutic composition has been formulated, it may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations may be stored either in a ready to use form or requiring reconstitution immediately prior to administration. The manner of administering formulations containing nucleic acid ligands for systemic delivery may be via subcutaneous, intramuscular, intravenous, intranasal or vaginal or rectal suppository.

The following Examples are provided to explain and illustrate the present invention and are not intended to be limiting of the invention. Example 1 describes the various materials and experimental procedures used in Examples 2-3. Example 2 describes VEGFR2 affinity selections. Example 3 describes VEGFR1 SELEX. Example 4 describes VEGFR2 SELEX on the mouse target Flk-1.

EXAMPLES

Example 1. VEGFR2 SELEX

Experimental Procedures

VEGFR2 for affinity selections was obtained from R&D Systems (Minneapolis, MN). The commercial preparation consists of the extracellular domain of human VEGFR2 (KDR; amino acid residues 1-764; Terman *et al.* (1992) Biochem. Biophys. Res. Commun. 187:1579-1586) fused to human IgG1 domain (also referred to as the Fc domain). The construct also contains a Factor Xa cleavage site between the KDR and the IgG1 domains and six histidine residues at the carboxy terminus. The protein is a disulfide-linked homodimer expressed in NSO mouse myeloma cell line. For affinity selections, KDR/Fc (50 µg) was digested with Factor Xa (2 µg; New England Biolabs) in 50 mM Tris HCl pH 8.0, 100 mM NaCl, 5 mM CaCl₂ at room temperature for 18 hours. The Fc fragment was

removed by incubation with Protein G-Sepharose for 1 hour at 4°C. Removal of Factor Xa is accomplished by treatment with 50 µl of Xarrest Agarose (Novagen, Madison, WI) for 15 minutes at room temperature. The KDR fragment was verified to be free of the Fc fragment and Factor Xa by SDS-PAGE on 4-12% acrylamide gradient gels and silver staining).

Example 2. VEGFR2 affinity selections

The SELEX process has been described in detail in the SELEX Applications. The purified KDR extracellular domain was immobilized on 4.5 µm polystyrene paramagnetic beads (Dynal, Lake Success, NY) by incubating the protein in 1.7 mL microfuge tubes overnight at 4°C in HEPES-buffered saline supplemented with 1 mM MgCl₂ and 1 mM CaCl₂ (HBSMC). The beads were then washed three times with 500 µL HBSMC followed by three 500 µL washes with HBSMC containing 0.01% human serum albumin and 0.05% tween 20 (HBSMCHT). Affinity selections were performed by mixing 0.2-50 µL of the bead slurry (0.6% solids w/v) containing about 0.075 µg/mL KDR extracellular domain (based on micro BCA assay) with 50-100 µL of RNA library 40N7 (5'-gggaggacgaugcgg [40N] cagacgacucgcccga-3') (SEQ ID NO:1), 2'-fluoropyrimidine RNA) in HBSMCHT (total volume 100 µL) buffer followed by incubation at 37°C for 30 minutes and washing with five times with 500 µL HBSMCHT. The beads were then transferred to a new microfuge tube in 500 µL HBSMCHT, the buffer was removed and the beads were resuspended in 20 µL water containing 5 µM 3' primer. Following heating to 95°C for 5 minutes and slow cooling to room temperature, 5 µL of 5X reverse transcriptase solution (0.5 M Tris/HCl, pH 9.0 at 21°C (pH 8.3 at 48°C), 2.5 M NaCl, 0.5 M Mg(OAc)₂, 0.5 M DTT, 5 mM dNTPs, 10 units AMV reverse transcriptase) was added to the tube and the contents were incubated at 48°C for 30 minutes. The beads were removed and the remainder of the reverse transcription mixture (25 µL) was added to 75 µL of PCR solution (66.7 mM KCl, 13.3 mM Tris/HCl, pH 8.3, 10 mM MgCl₂, 1.33 mM dNTP, 1.33 µM 3' N7 primer, 0.667 µM 5' N7 primer, 0.667 µM 5' primer-FD2, 2.67 µM 5-(and 6-) carboxy-X-rhodamine, 5 units Taq polymerase). Thirty-five cycles of PCR were performed (after the initial heating at 95°C for 3 minutes, each cycle consisted of 95°C for 15 sec, 55°C for 10 sec, 72°C for 30 sec). *In vitro* transcriptions were performed by mixing 50 µL of the PCR product with 150 µL of the transcription solution (4 mM 2'-F CTP, 4 mM 2'-F UTP, 1.33 mM ATP, 1.33 mM GTP, 6.67 mM guanosine, 0.267 M

Hepes/KOH, pH 8.0, 0.267 M MgCl₂, 0.267 M spermidine, 0.267 M DTT, 0.2 units pyrophosphatase, 660 units T7 RNA polymerase) and incubated at 37°C overnight. The transcripts were purified by gel electrophoresis following a brief DNase treatment to remove the template. The conditions for the six affinity selections performed and the amount of
5 RNA bound at each round is given in **Table 1**.

Examination of the K_d values of affinity enriched pools from rounds 1-6 (**Table 1**) reveals that a substantial improvement in affinity occurred already by round 2, with little, if any subsequent improvement in affinity. To address the formal possibility that the aptamers have evolved to the residual Fc domain contaminant in the factor Xa-cleaved preparation, the
10 binding of the random starting pool (round 0) and round 5 pool to KDR/Fc and cMet/Fc was examined. The two Fc-containing constructs were obtained from the same manufacturer (R&D Systems), were expressed in the same cell type (NSO cells) and have identical Fc regions including the six histidines at the carboxy terminus. For KDR/Fc, the K_d values for aptamer pools from rounds 0 and round 5 were 361 ± 16 nM and 0.76 ± 0.22 nM,
15 respectively. The same two pools bound to cMet/Fc with K_d values of 58 ± 9 nM and 74 ± 6 nM. These data suggest that the binding epitope for aptamers in the round 5 pool is the KDR domain, as expected.

Sequences of 30 individual aptamer clones were obtained from the round 5 affinity enriched pool. Most of the sequences (19) could be grouped into a family shown in **Table 2**
20 (group A). Clones without obvious sequence similarity to members of family A are shown in **Table 3** and are referred to as group B. Predicted secondary structures for representative aptamers from group A are shown in **Figure 1**. It is of interest to note that two of the aptamers in group A have circularly permuted primary structures compared to the rest of the aptamers in the group (**Figure 1**). This result suggests that the regions outside of the
25 conserved motif shown in **Figure 1** (shading indicates conserved region) are not critical for high affinity binding. We have measured the binding affinity of a subset of aptamers from both groups A and B to KDR/Fc using the nitrocellulose filter binding method. High affinity aptamers were found in both group A and B (**Tables 2 and 3**).

We next examined whether a group of representative aptamers was able to inhibit the
30 binding of ¹²⁵I-VEGF-165 to VEGF receptors expressed on HUVECs. Cells were seeded in 96-well plates at a density of about 10,000 cells/well and maintained until confluent. Culture medium was then replaced with growth factor deficient medium (MEM, 5% heat inactivated fetal bovine serum, 1 µg/mL heparin) for 3-4 hours. Cells were then washed with Dulbecco's

phosphate-buffered saline (DPBS) (containing 1 mM CaCl₂, 1 mM MgCl₂ and 0.1% bovine serum albumin) followed by the addition of 100 µL/well of DPBS. ¹²⁵I-VEGF-165 (10 mg/mL) in the presence of varying amounts of aptamers (0.001-1000 nM) was then added to cells for 2 hours at room temperature. Unbound ¹²⁵I-VEGF-165 was then removed by washing with DPBS and the cells were lysed with Triton X-100. Lysates were harvested onto glass fiber filters plates and processed for scintillation counting. Aptamers K1, K10, K17 and K21 were tested. Aptamer K1 did not displace ¹²⁵I-VEGF-165 at concentrations up to 1000 nM. Aptamers K17 and K21 inhibited ¹²⁵I-VEGF-165 receptor binding with IC₅₀ values of 163 and 79 nM, respectively. Aptamer K10 was the most potent inhibitor of receptor binding with an IC₅₀ of 1 nM. Thus, among the VEGFR2 aptamers tested, both receptor binding antagonists and non-antagonists have been identified.

Example 3. VEGFR1 SELEX

VEGFR1 SELEX was conducted in a similar manner to that described above for VEGFR2. For affinity selections, we used VEGFR1 (Flt-1) extracellular domain fused to the Fc domain. Like KDR/Fc, Flt-1/Fc (R&D Systems, Minneapolis, MN) construct also contains a Factor Xa cleavage site between the Flt-1 and the IgG1 domains and six histidine residues at the carboxy terminus. The protein is a disulfide-linked homodimer expressed in NSO mouse myeloma cell line.

Examination of the K_d values of affinity enriched pools from rounds 0 and 5 (Table 4) reveals that a only a modest improvement in affinity occurred already by round 5. This is probably due to the very high affinity of the extracellular domain of VEGFR1 for nucleic acids, as reflected by the K_d value of 0.20 ± 0.05 nM.

Example 4. Mouse VEGFR2 (Flk-1) SELEX

The human VEGFR2 (KDR) SELEX was performed as previously described. However, in spite of >90% homology between mouse and human VEGFR2, no KDR clonal isolates showed any affinity to Flk-1. Moreover, the evolved aptamer pools from which the clones were derived showed a 10³ fold loss in affinity accompanied by a three fold loss in total binding (plateau). It seemed unlikely that suitable Flk-1 aptamers could be screened from these pools. Therefore, additional rounds of SELEX were performed beginning with round 4 RNA from the human SELEX on the mouse target, Flk-1. Four

rounds of Flk-1 SELEX were performed with Protein A paramagnetic beads, followed by three rounds of SELEX with Flk-1 bound to hydrophobic beads.

Mouse VEGFR2 (Flk-1)/Fc Chimera (R&D Systems Inc.) was fixed to Protein A paramagnetic beads (DynaL Inc.) per manufacturer's instructions for four hours at room temperature. The Flk-1 loaded beads were washed five times in 500 μ L HBS supplemented with 1 mM Mg^{2+} , 1 mM Ca^{2+} , 0.01% BSA and 0.05% TWEEN-20, (HBS+) and resuspended in 100 μ L HBS+. The estimated maximum Flk-1/bead stock concentration is 360 nM. The first round of Flk-1 SELEX was at 36 nM Flk-1 and 180 nM round 4 RNA from the KDR SELEX, a five-fold excess, in 100 μ L HBS. RNA and Flk-1 were incubated together with rocking at 37°C for one hour and washed 5X in 500 μ L HBS+. The second, third and fourth rounds followed the same protocol, except that the estimated Flk-1 concentration was dropped 5 fold at each round. After four rounds of SELEX, the partition scheme was switched to Flk-1 bound hydrophobically to Dynal M450 beads. The estimated starting concentration of Flk-1 was 36 nM, round 2 [Flk-1] = 3.6 nM and round 3 [Flk-1] = 100 pM. Background estimates were obtained by treating beads without Flk-1 in the same manner and comparing PCR product yields. RNA from round three was eluted reverse transcribed and PCR amplified in the usual manner. This PCR product was gel purified and cloned into pPCR-Script Amp vector following manufacturer's instructions (Stratagene). Clones were randomly selected and plasmid DNA was purified by a 96 well format, QIAprep 96 Turbo Miniprep (Qiagen). Sequence data is not shown.

Binding constants were obtained for RNA pools at various rounds and compared. The results are set forth in **Figure 2**. Rd-3 refers to RNA from the first phase of Flk-1 SELEX where Flk-1 is bound to paramagnetic beads through an IgG-Protein A interaction. Rd M3 refers to round 3 of the SELEX where Flk-1 is bound hydrophobically to M450 beads. Both Flk-1 and CD-28 proteins are cloned chimeras and are expressed with IgG motifs to which RNA can bind. CD-28 was chosen for affinity determination to test for possible binding to the IgG portion of the target. Rd M3 RNA shows no affinity to CD-28 in this test, implying that the Rd M3 affinity to Flk-1 is not through an interaction with IgG. Rd-M3-Background refers to RNA transcribed from PCR products amplified from beads that did not contain Flk-1. This RNA has no affinity for Flk-1.

Table 1. SELEX results for rounds 1-6.

The number of molecules bound was determined by quantitative PCR. Nitrocellulose filter binding was used to determine the K_d for each of the pools using ^{32}P end-labeled transcripts and KDR/Fc dimer (in HBSMC buffer at 37°C). The affinity of the unselected randomized starting library is 36 ± 3 nM.

Round	Bead volume, μl	[RNA], μM	Molecules RNA bound to KDR beads	Molecules RNA bound to empty beads	Signal/noise	K_d pool, nM
1	50	5	3.2×10^9	1.0×10^9	3.2	Not determined
2	50	2	1.8×10^{10}	4.9×10^7	367	0.68 ± 0.14
3	10	6.1	3.3×10^{10}	2.1×10^8	157	0.80 ± 0.16
4	2	2.5	9.4×10^9	5.5×10^7	171	0.581 ± 0.08
5	0.4	5	8.5×10^8	3.8×10^7	22	0.83 ± 0.12
6	0.2	2.5	2.0×10^8	5.2×10^7	3.8	0.44 ± 0.05

Table 2. (Page 1) Aligned sequences a family of VEGFR2 aptamers.

Nucleotides from the fixed and initially randomized regions are shown in lowercase and uppercase letters, respectively. Highly conserved nucleotides are shown in boldface letters. Regions predicted to be base-paired are underlined. The last two sequences in the set are circularly permuted and are split between two lines (with equality sign) to allow alignment with the other sequences. K_d values for a subset of aptamers tested for binding to KDR/Fc are shown.

Clone	SEQ ID NO:	SEQUENCE	K_d , nM
K3	2	gggaggacgaugcggCAUGGGGCCUGACU- <u>GGAUCAUACCA</u> CGGUUCUCUGGUcagacgacucgccccga	0.51 ± 0.14
K5	3	gggaggacgaugcggCAUGGGGCCUGACU- <u>GGAUCAUACCA</u> CGGUUCUCUGGUcagacgacucgccccga	0.44 ± 0.07
K102 (n=2)	4	gggaggacgaugcggCAUGGGGCCUGACU- <u>GGAUCAUACCA</u> CGGUUCUCUGGUcagacgacucgccccga	30
K119	5	gggaggacgaugcggCCUGGGGCCUGACU- <u>GGAUCAUACCA</u> CGGUUCUCUGGUcagacgacucgccccga	
K7	6	gggaggacgaugcggAC-GAUAACACAGGGCCUGCUU- <u>GGAUCA</u> CACUGAUUGCGCCcagacgacucgccccga	
K17	7	gggaggacgaugcggACANAUAAACAGGGCCUGCUU- <u>GGAUCA</u> CACUGAUUGCGCCcagacgacucgccccga	0.46 ± 0.02
K124	8	gggaggacgaugcggCGAUAAACAGGGCCUGCUU- <u>GGAUCA</u> CACUGAUUGCGCCcagacgacucgccccga	0.24 ± 0.08
K103 (n=3)	9	gggaggacgaugcggACGAUAAACAGGGCCUGCUU- <u>GGAUCA</u> CACUGAUUGCGCCcagacgacucgccccga	0.07 ± 0.01
K1	10	gggaggacgaugcggGGCCUGUUU- <u>GGAUCAUACCGAU</u> CGUCAAUCCAAGAGUGGUcagacgacuc...	

Table 2. (Page 2)

Clone	SEQ ID NO:	SEQUENCE	K _d nM
K2	11 (n=4)	gggaggacgaugcggggcccguguu- <u>ggaucauac</u> <u>cggaucguc</u> <u>aaucua</u> aaaguggucagacgacuc...	0.27 ± 0.03
K101	12 (n=7)	gggaggacgaugcggggcccguguu- <u>ggaucauac</u> <u>cggaucguc</u> <u>aaucua</u> aaaguggucagacgacugccccga	
K115	13 (n=2)	gggaggacgaugcggggcccguguu- <u>ggaucauac</u> <u>cggaucguc</u> <u>aagccua</u> aaaguggucagacgacugccccga	
K118	14 (n=3)	gggaggacgaugcggucgaagauaagggcccguguu- <u>ggaucauac</u> <u>cggaucguc</u> <u>cgccguc</u> agacgacugccccga	
K136	15	gggaggacgaugcggaggcccuauuc- <u>ggaucauac</u> <u>ucgcaguu</u> <u>uuua</u> ccccgucagacgacugccccga	
K121	16	gggaggacgaugcggaggcccuauuc- <u>ggaucauac</u> <u>ucgcaguu</u> <u>uuac</u> ccccgucagacgacugccccga	
K127	17	gggaggacgaugcggggcccuauuc- <u>ggaucauac</u> <u>ucgcaguu</u> <u>uuac</u> ccccgucagacgacugccccga	
K110	18	gggaggacgaugcggaggucucuuu <u>ggaa</u> <u>cuu</u> - <u>guuuu</u> <u>ugucuc</u> <u>ccggguc</u> agacgacugccccga	0.26 ± 0.05
K21	19	5' gggaggacgaugcggaucauac <u>ccga</u> <u>agaga</u> = =CACGGGGCCACCAU <u>UCCUCA</u> CCCCcagacgacugccccga3'	0.97 ± 0.08
K24	20	5' gggaggacgaugcggaucauac <u>ccggg</u> <u>uaua</u> = =ACACCGNUCA <u>CGGGCCU</u> UNUCGucagacgacugccccga3'	

Table 3. Ungrouped sequences of VEGFR2 aptamers showing only the initially randomized region.
K_d values for a subset of aptamers tested for binding to KDR/Fc are shown.

<u>Clone</u>	<u>SEQ ID</u>	<u>NOS.</u>	<u>Sequence</u>	<u>K_d, nM</u>
K4		21	AGGUGCUCUUUGGAA CUUCGUUUUGUCUGCUCUCCUGGU	0.28 ± 0.04
K10		22	UUGAUCGAGGUUCUAAGGCCUAUUUCCUGACUUUCUCCCC	0.47 ± 0.25
K11 (n=4)		23	UUGAUCGAGGUUCUAAAGCCUAUUUCCUGACUUUCUCCCC	0.61 ± 0.13
K12		24	AAACGGAGAAUUGGAGACCGACGUCGACCUUUGGCCCC	15.4 ± 2
K108		25	UUGAUCGAGGUUCUAAAGCCUAUUUCCUGACUUUCUCCCC	
K109 (n=4)		26	ACGAUGCGGAAUCAGUGAAUGCUUAUAGCUCGCGCUGGU	
K111		27	AGCCGCCAGAAUUGGAACAACCCUUUCGACGCUCCCC	
K116		28	CGAAACGGAAUACUUGGAUACACCGCACUUCGACCCCU	
K6		29	AGCACUUGACCCACNACCAGAAAGCCAGCC	0.98 ± 0.05
K13		30	AACCAAUUAAAGUCUGGCAAAUCUCUCUGUG	0.75 ± 0.09
K23		31	ACACACACAUCAUAAACAUAUUGCCGUUGAC	2.2 ± 0.2

Table 4. SELEX results for rounds 1-6.

The number of molecules bound was determined by quantitative PCR. Nitrocellulose filter binding was used to determine the K_d for each of the pools using ^{32}P end-labeled transcripts and Flt-1/Fc dimer (in HBSCMC buffer at 37°C). The affinity of the unselected randomized starting library: 0.20 ± 0.05 nM. ND = not determined.

Round	Bead volume, μl	[RNA], μM	Molecules RNA bound to KDR beads	Molecules RNA bound to empty beads	Signal/noise	K_d pool, nM
1	50	2.7	2.6×10^{10}	1.5×10^8	173	ND
2	25	2	2.1×10^{12}	1.2×10^8	17500	ND
3	2.5	1.5	3.6×10^{11}	7.2×10^7	5000	ND
4	0.25	1.5	6.2×10^{10}	8.6×10^7	721	ND
5	0.025	1.5	1.1×10^{10}	8×10^6	1375	0.093 ± 0.037

We claim:

1. A method of identifying nucleic acid ligands to a vascular endothelial growth factor (VEGF) receptor, comprising:

a) contacting a candidate mixture of nucleic acids with a VEGF receptor, wherein nucleic acids having an increased affinity to a VEGF receptor relative to the candidate mixture may be partitioned from the remainder of the candidate mixture.

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

c) amplifying the increased affinity nucleic acids to yield a ligand enriched mixture of nucleic acids, whereby nucleic acid ligands to a VEGF receptor may be identified.

2. The method of claim 1 wherein said candidate mixture of nucleic acids is comprised of single stranded nucleic acids.

3. The method of claim 2 wherein said single stranded nucleic acids are ribonucleic acids.

4. The method of claim 1 further comprising:

d) repeating steps a), b), and c).

5. The method of claim 3 wherein said candidate mixture of nucleic acids comprises 2 position modified pyrimidines.

6. The method of claim 5 wherein said modified pyrimidines are 2'-F modified pyrimidines.

7. A nucleic acid ligand to a vascular endothelial growth factor (VEGF) receptor identified according to the method comprising:

a) contacting a candidate mixture of nucleic acids with a VEGF receptor wherein nucleic acids having an increased affinity to a VEGF receptor relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;

b) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and

c) amplifying the increased affinity nucleic acids to yield a ligand-enriched mixture of nucleic acids, whereby a nucleic acid ligand to a VEGF receptor may be identified.

8. A purified and isolated non-naturally occurring nucleic acid ligand to a VEGF receptor.

9. The nucleic acid ligand of claim 8 which is a ribonucleic acid.

10. The nucleic acid ligand of claim 9 wherein the VEGF receptor is selected from the group consisting of VEGFR1, VEGFR2, VEGFR3, and neuropilin-1.

11. The nucleic acid ligand of claim 10 wherein the VEGF receptor is VEGFR2.

5 12. The nucleic acid ligand of claim 11 wherein said ligand has been chemically modified at the ribose and/or phosphate and/or base positions.

13. The nucleic acid ligand of claim 12 wherein said ligand is comprised of 2'-F modified nucleotides.

10 14. The nucleic acid ligand of claim 13 wherein said ligand is selected from the group consisting of the sequences set forth in Tables 2 and 3, and Figure 1 (SEQ ID NOS:2-36).

40030725.013102

10/030725

11 JAN 2002

ABSTRACT

Methods are described for the identification and preparation of high-affinity nucleic acid ligands to a VEGF receptor. Included in the invention are specific RNA ligands to a VEGF receptor identified by the SELEX method. Also included are RNA ligands that inhibit the interaction of a VEGF receptor with VEGF.

10030725.013102




FIGURE 1




Fig. 2

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

Page 1 of 1
Docket No. NEX88/PCT-US

As a below named inventor, I hereby declare that:
My residence, post office address and citizenship are as stated below next to my name.

I believe I am the sole, original and first inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **HIGH AFFINITY VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR NUCLEIC ACID LIGANDS AND INHIBITORS**, the specification of which:

- ☐ is attached hereto.
☒ was filed on **July 26, 2000** as United States Application Serial No. _____ or PCT International Application Number **PCT/US00/20478** and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 USC §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Number: _____ Country: _____ Date Filed: (day/mo/yr) _____ Priority not claimed ☐
I hereby claim the benefit under 35 USC §119(e) of any United States provisional application(s) listed below.

Application Number: _____ Filing Date: (mo/day/yr) _____

I hereby claim the benefit under 35 USC §120 of any United States application(s), or §365(c) of any PCT International application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 USC §112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application Number: _____ Filing Date: (mo/day/yr) _____ Status - patented, pending, abandoned
09/364,540 07/29/99 Pending

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

12 Barry J. Swanson, #33,215

Thomas D. Bratschun, #32,966

Margaret M. Wall, #33,462

Max D. Hensley, #27,043

CUSTOMER NO: 25,871

Address all telephone calls to:

Address all correspondence to:

Rosemary Kellogg, #39,726

Darla G. Yoerg, #48,053

Dan Shifrin #34,473

Mark Bosse, #35,071

James L. Brown, #48,576

Steven N. Hird, #P-51,112

Diane Cruz, #33,960

Barry J. Swanson at telephone number 303-268-0066

Barry J. Swanson

Swanson & Bratschun, L.L.C.

1745 Shea Center Drive, Suite 330

- Highlands Ranch, Colorado 80129

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 USC §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor (given name, family name): Nebojsa Janjic

Inventor's signature: Nebojsa Janjic

Residence: Boulder, Colorado


Post Office Address: 6976 Carter Trail
Boulder, Colorado 80501

Date: 1-25-02

Citizenship: US USX

■ Additional inventors are being named on separately numbered sheets attached hereto.

Full name of second joint inventor (given name, family name): Larry Gold

Inventor's signature: 

Residence: Boulder, Colorado

Post Office Address: 1033 5th Street
Boulder, Colorado 80302

Date: 1/24/02

Citizenship: US

S:\Client Folders\NeXstar\Nex88\PCT\US\Declaration.doc

2002-01-24 10:30:26

SEQUENCE LISTING

<110> NEXSTAR PHARMACEUTICALS, INC.

<120> High Affinity Vascular Endothelial Growth Factor (VEGF)
Receptor Nucleic Acid Ligands and Inhibitors

<130> NEX 88/PCT

<140>

<141>

<150> 09/364,540

<151> 1999-07-29

<160> 36

<170> PatentIn Ver. 2.0

<210> 1

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F; N at positions 16 - 55 is
any base.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 1

gggaggacga ugcggnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnncagac 60
gacucgcccg a 71

<210> 2

<211> 70

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(70)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 2

gggaggacga ugcggcaugg ggcugacug gaucauacca ccgcuuucuc uggucagacg 60
acucgcccga 70

<210> 3

<211> 70

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(70)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 3

gggaggacga ugcggcaugg ggcugacug gaucauacca ccgcuuccuc uggucagacg 60
acucgcccga 70

<210> 4

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 4

gggaggacga ugcggcaugg ggcugacug gaucauacca ccgcuuccuc ugggucagac 60
gacucgcccg a 71

<210> 5

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 5

gggaggacga ugcggccugg ggccugacug gaucauacca ccgcuuccuc ugggucagac 60
gacucgccc a 71

<210> 6

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 6

gggaggacga ugcggacgau aacacagggc cugcuuggau cacacugauu gcgcccagac 60
gacucgccc a 71

<210> 7

<211> 72

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(72)

<223> All pyrimidines are 2'F; n at position 19 is any
base.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 7

gggaggacga ugcggacana uaacacaggg ccugcuugga ucacacugau ugcgccagga 60
cgacucgccc ga 72

<210> 8
<211> 70
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(70)
<223> All pyrimidines are 2'F.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 8
gggaggacga ugcggcgaua acacagggcc ugcuuuggauc acacugauug cgcccagacg 60
acucgcccga 70

<210> 9
<211> 71
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(71)
<223> All pyrimidines are 2'F.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 9
gggaggacga ugcggacgau aacacagggc cugcuuggau cacacugauu gcgccagac 60
gacucgcccga a 71

<210> 10
<211> 71
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(71)
<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 10

gggaggacga ugcggggccu guuuggauca uaccgaucgu caauccaaga guggucagac 60
gacucgccc a 71

<210> 11

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 11

gggaggacga ugcggggccu guuuggauca uaccgaucgu caauccuaaa guggucagac 60
gacucgccc a 71

<210> 12

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 12

gggaggacga ugcggggccu gcuuggauca uaccgaucgu caauccuaaa guggucagac 60
gacucgccc a 71

<210> 13

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 13

gggaggacga ugcggggccu gcuuggauca uaccgaucgu caagccuaaa guggucagac 60
gacucgccccg a 71

<210> 14

<211> 70

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(70)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 14

gggaggacga ugcggucuga agaguaaggg gccuguucgg aucacaccug ccgucagacg 60
acucgccccga 70

<210> 15

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 15

gggaggacga ugcggagggc cuauucggau cauacucgca guucuuuuac cccgucagac 60
gacucgcccga a 71

<210> 16
<211> 69
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(69)
<223> All pyrimidines are 2'F.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 16
gggaggacga ugcggagggc cuauucggau cauacucgca guucuuaccc cgucagacga 60
cucgcccga 69

<210> 17
<211> 69
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(69)
<223> All pyrimidines are 2'F.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 17
gggaggacga ugcggggggc uaacuuggau caucagcacc ugccaccacc ccucagacga 60
cucgcccga 69

<210> 18
<211> 70
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(70)
<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 18

gggaggacga ugcggaggug cuccuuugga acuucguauu ugucugcucc cggucagacg 60
acucgcccga 70

<210> 19

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 19

gggaggacga ugcggaucau accgaagaga cacggggcca ccuaucucc acccccagac 60
gacucgcccg a 71

<210> 20

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F; n at positions 38 and 51
is any base.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 20

gggaggacga ugcggaucau accgggucau aacaccgnuc acggggccuu nucgucagac 60
gacucgcccg a 71

<210> 21

<211> 70

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(70)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 21

gggaggacga ugcggaggug cuccuuugga acuucguauu ugucugcucc uggucagacg 60
acucgcccga 70

<210> 22

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 22

gggaggacga ugcgguugau cgagguucua aggccuauuu ccugacuuuc uccccagac 60
gacucgcccg a 71

<210> 23

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 23
 gggaggacga ugcgguugau cgagguucua aagccuauuu ccugacuuuc uccccagac 60
 gacucgcccga a 71

<210> 24
 <211> 70
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> modified_base
 <222> (1)..(70)
 <223> All pyrimidines are 2'F.

<220>
 <223> Description of Artificial Sequence: Synthetic
 Sequence

<400> 24
 gggaggacga ugcggaacg gaagaauugg agaccgacgu cgaccucuug gccccagacg 60
 acucgcccga 70

<210> 25
 <211> 70
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> modified_base
 <222> (1)..(70)
 <223> All pyrimidines are 2'F.

<220>
 <223> Description of Artificial Sequence: Synthetic
 Sequence

<400> 25
 gggaggacga ugcgguugau cgagguucua aagccuauuu cugacuuuc cccccagacg 60
 acucgcccga 70

<210> 26
 <211> 70
 <212> RNA
 <213> Artificial Sequence

<220>
 <221> modified_base
 <222> (1)..(70)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic Sequence

<400> 26

gggaggacga ugcggacgau gcggaauacag ugaauucuua uagcuccgcc uggucagacg 60
acucgcccga 70

<210> 27

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic Sequence

<400> 27

gggaggacga ugcggaagcc gccagaauug gaacaacccc uuucgcacgc uccccagac 60
gacucgcccg a 71

<210> 28

<211> 71

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(71)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic Sequence

<400> 28

gggaggacga ugcggcgaaa cggaauacuu ggauacaccg cacuucccga cccucagac 60
gacucgcccg a 71

<210> 29

<211> 61

<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(61)
<223> All pyrimidines are 2'F; n at position 30 is any
base.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 29
gggaggacga ugcggagcac uugacccacn accagaaagc cagcccagac gacucgcccg 60
a 61

<210> 30
<211> 61
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(61)
<223> All pyrimidines are 2'F.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 30
gggaggacga ugcggaacca auuaagucug gcaaaucucu cugugcagac gacucgcccg 60
a 61

<210> 31
<211> 61
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(61)
<223> All pyrimidines are 2'F.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 31
gggaggacga ugcggacaca cacaucuaaa acauuguccg uugaccagac gacucgcccg 60
a 61

<210> 32
<211> 64
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(64)
<223> All pyrimidines are 2'F.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 32
gggaggacga ugcgggcggc auggggcccug acuggaucu accaccgcca gacgacucgc 60
ccga 64

<210> 33
<211> 63
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base
<222> (1)..(63)
<223> All pyrimidines are 2'F.

<220>
<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 33
gggaggacga ugcgguaaca cagggccugc uuggaucaca cugauugcag acgacucgcc 60
cga 63

<210> 34
<211> 67
<212> RNA
<213> Artificial Sequence

<220>
<221> modified_base

<222> (1)..(67)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 34

gggaggacga ugcgggacga ugcggggccu guuuggauca uaccgaucgu ccagacgacu 60
cgccccga 67

<210> 35

<211> 59

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(59)

<223> All pyrimidines are 2'F.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 35

gggaggacga ugcggcggaug cauaccgaag agacacgggg ccacagacga cugccccga 59

<210> 36

<211> 68

<212> RNA

<213> Artificial Sequence

<220>

<221> modified_base

<222> (1)..(68)

<223> All pyrimidines are 2'F; n at position 41 is any
base.

<220>

<223> Description of Artificial Sequence: Synthetic
Sequence

<400> 36

gggaggacga ugcggcggaug cauaccgggu cauaacaccg nucacggggc cucagacgac 60
ucgccccga 68